TD Cowen maintained a Buy rating on Boston Scientific on June 25, 2026.
1 report, 1 independent
Updated Jun 25
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen maintained a Buy rating on Boston Scientific on June 25, 2026.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
-
Boston Scientific
worldwide developer, manufacturer and marketer of medical devices
Related events
- TD Cowen issued a buy rating and price target for Evolv Technologies Holdings, Inc.
- TD Cowen maintained a Buy rating on Forgent on September 15, 2026.
- TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.
- Truist Financial and TD Cowen raised target prices and issued buy ratings for Astrana Health, Inc. on June 10, 2026.
- TD Cowen downgraded Capri's rating and lowered its price target.